BDWM
PRLD icon

Brewin Dolphin Wealth Management’s Prelude Therapeutics PRLD Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$9K Hold
1,699
– – ﹤0.01% 291
2022
Q1 		$12K Hold
1,699
– – ﹤0.01% 281
2021
Q4 		$21K Buy
+1,699
New +$27.6K ﹤0.01% 259

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brewin Dolphin Wealth Management's PRLD Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its Prelude Therapeutics (PRLD) position steady in Q2 2022 at 1,699 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #291.

Brewin Dolphin Wealth Management first reported a position in PRLD in Q4 2021 and has held it in 3 quarters since. The position peaked at $21K in Q4 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

  • Brewin Dolphin Wealth Management held 1,699 shares of Prelude Therapeutics worth $9K as of Q2 2022.
  • Brewin Dolphin Wealth Management left its Prelude Therapeutics share count unchanged in Q2 2022.
  • Prelude Therapeutics made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #291 holding.
  • Brewin Dolphin Wealth Management first reported a position in Prelude Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • Brewin Dolphin Wealth Management's Prelude Therapeutics position peaked at $21K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.